{"id":"h1-data-minimalism","assumption":"More comprehensive multi-modal datasets always improve drug repurposing predictions","hypothesis":"Strategically minimal, high-signal datasets can outperform large, noisy multi-modal approaches for rare diseases","impact":"Could unlock repurposing for ultra-rare conditions with extremely limited data","timestamp":"2025-08-12T22:58:00.000Z","status":"proposed"}
{"id":"h2-actionability-first","assumption":"Predictive accuracy is the primary success metric for AI drug repurposing systems","hypothesis":"Models optimized for clinical actionability (interpretability, uncertainty quantification, decision support) outperform accuracy-optimized models","impact":"Could bridge the gap between AI predictions and clinical implementation","timestamp":"2025-08-12T22:58:00.000Z","status":"proposed"}
{"id":"h3-cross-disease-patterns","assumption":"Each rare disease requires disease-specific computational models and approaches","hypothesis":"Shared mechanistic patterns across rare diseases can be leveraged through transfer learning and meta-learning approaches","impact":"Could enable repurposing for diseases with insufficient individual datasets","timestamp":"2025-08-12T22:58:00.000Z","status":"proposed"}
{"id":"h4-parallel-validation","assumption":"Drug validation must follow sequential preclinical â†’ clinical stages","hypothesis":"Parallel, multi-stage validation using real-world evidence can accelerate repurposing timelines without compromising safety","impact":"Could dramatically reduce time-to-treatment for rare disease patients","timestamp":"2025-08-12T22:58:00.000Z","status":"proposed"}
{"id":"h5-human-ai-collaboration","assumption":"AI should minimize human bias and replace expert judgment in drug repurposing","hypothesis":"Hybrid human-AI systems that amplify rather than replace clinical expertise outperform fully automated approaches","impact":"Could leverage irreplaceable rare disease expertise while scaling discovery","timestamp":"2025-08-12T22:58:00.000Z","status":"proposed"}